CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 3, April 2013
AFRICA
85
cols for surveillance of post-streptococcal sequelae: acute rheumatic
fever, rheumatic heart disease and acute post-streptococcal glomerulo-
nephritis. National Institutes of Allergy and Infectious Disease, 2006.
-
lae.pdf.
13. McKee PA, Castelli WE, McNamara PM, Kannel WB. The natural
history of congestive heart failure: the Framingham study.
New Engl J
Med
1971;
285
: 1441–1446.
14. Special writing group of the committee on rheumatic fever. Guidelines
for the diagnosis of acute rheumatic fever: Jones criteria.
J Am Med
Assoc
1992;
268
: 2068–2073.
15. Rheumatic fever and rheumatic heart disease: report of a WHO expert
consultation, Geneva, 29 October – 1 November 2001. Geneva: World
Health Organization, 2004.
16. Mylonakis E, Calderwood SB. Infective endocarditis in adults.
N Engl
J Med
2001;
345
: 1318–1330.
17. Prineas RJ, Rischard SC, Blackburn H.
The Minnesota Code Manual
of Eelectrocardiographic Findings: Standards and Procedures for
Measurement and Classification
. Boston, MA: John Wright, 1982.
18. Barst RJ, McGoon M, Torbicki A,
et al
. Diagnosis and differential
assessment of pulmonary arterial hypertension.
J Am Coll Cardiol
2004;
43
(Suppl): 40S–47S.
19. Muna WFT. Cardiovascular disorders in Africa.
World Health Stat Q
1993;
46
: 125–126.
20. Ravisha MS, Tullu MS, Kamat JR. Rheumatic fever and rheumatic
heart disease: clinical profile of 550 cases in India.
Arch Med Res
2003;
34
: 382–387.
21. Kayima J, Mungoma M, Mondo C, Freers J. The changing pattern of
cardiac disease in Africa: the Ugandan experience.
Cardiovasc J Afr
2011;
22
: S9.
22. Kumar R. Controlling rheumatic heart disease in developing countries.
World Health Forum
1995;
16
: 47–51.
23. Jaine R, Baker M, Venugopal K. Acute rheumatic fever associated with
household crowding in a developed country.
Pediatr Infect Dis J
2011;
30
: 315–319.
24. Vahanian M, Baumgartner H, Bax J,
et al
. Guidelines on the manage-
ment of valvular heart disease: The Task Force on the Management of
Valvular Heart Disease of the European Society of Cardiology.
Eur
Heart J
2007;
28
: 230.
25. Tornos P, Sambola A, Permanyer-Miralda G,
et al
. Long-term outcome
of surgically treated aortic regurgitation: Influence of guideline adher-
ence toward early surgery.
J Am Coll Cardiol
2006;
47
: 1012.
26. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP,
et
al.
Focused update incorporated into the ACC/AHA 2006 guidelines
for the management of patients with valvular heart disease: A report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Writing Committee to Revise the
1998 Guidelines for the Management of Patients with Valvular Heart
Disease): Endorsed by the Society of Cardiovascular Anesthesiologists,
Society for Cardiovascular Angiography and Interventions, and Society
of Thoracic Surgeons.
Circulatio
n 2008;
118
: e523–661.
27. Harikrishnan S, Kartha CC. Pulmonary hypertension in rheumatic heart
disease.
Pulmon Vasc Res Inst Rev
2009;
1
: 13–19.
28. Bahl V, Chandra S, Talwar K, Kaul U, Sharma S,
et al.
Balloon mitral
valvotomy in patients with systemic and suprasystemic pulmonary
artery pressures.
Catheter Cardiovasc Diagn
1995;
36
: 211–215.
29. Jones T. Diagnosis of rheumatic fever.
J Am Med Assoc
1944;
126
:
481–484.
30. Essop MR, Wisenbaugh T, Sareli P. Evidence against a myocardial
factor as a cause of ventricular dilatation in active rheumatic carditis.
J
Am Coll Cardiol
1993;
22
: 826–829.
31. Kassem AS, Zaher SR, Abou Shleib H, el-Kholy AG, Madkour AA,
et
al
. Rheumatic fever prophylaxis using benzathine penicillin G (BPG):
two week versus four-week regimens: comparison of two brands of
BPG.
Pediatrics
1996;
97
: 992–995.
32. Lue HC, Wu MH, Wang JK, Wu FF, Wu YN. Three- versus four-week
administration of benzathine penicillin G: effects on incidence of
streptococcal infections and recurrences of rheumatic fever.
Pediatric
s
1996;
97
: 984–988.
33. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk
factor for stroke: The Framingham Study.
Stroke
1991;
22
: 983–988.
34. Schopka S, Christof S, Andreas K, Kortner A, Tafelmeier A,
et al
.
Ablation of atrial fibrillation with the Epicor system: a prospective
observational trial to evaluate safety and efficacy and predictors of
success.
J Cardiothorac Surg
2010;
5
: 34.
35. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute
stroke with atrial fibrillation. The Copenhagen Stroke study.
Stroke
1996;
27
: 1765–1769.
36. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG.
Prevalence, age distribution, and gender of patients with atrial fibrilla-
tion. Analysis and implications.
Arch Intern Med
1995; 155: 469–473.
37. Kakkar N, Kaur R. Knowledge base of clinicians regarding oral anti-
coagulant therapy in a teaching institution – a questionnaire survey
. J
Assoc Physicians India
2004;
52
: 868–872.
38. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the
optimal level for Chinese patients on warfarin therapy for moderate-
intensity anticoagulation?
Br J Clin Pharmacol
2005;
59
: 582–587.
39. Roy D, Marchand E, Gagné P, Chabot M, Cartier R. Usefulness of anti-
coagulant therapy in the prevention of embolic complications of atrial
fibrillation.
Am Heart J
1986;
112
: 1039–1043.
40. Kakkar N, Kaur R, John M. Outpatient oral anticoagulant management
– an audit of 82 patients.
J Assoc Physicians India
2005;
53
: 847–852.
41. Wyse DG, Waldo AL, DiMarco JP,
et al
. Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM) investigators. A
comparison of rate control and rhythm control in patients with atrial
fibrillation.
N Engl J Med
2002;
347
: 1825–1833.
42. Reményi B, Wilson N, Steer A, Ferreria B, Kado J, Kumar K,
et al.
World Heart Federation criteria for echocardiographic diagnosis of
rheumatic heart disease – an evidence-based guideline.
Nat Rev Cardiol
2012;
5
: 297–309.
